2076975 2077203
최종편집 2024-03-29 18:51 (금)
Global big pharma earnings amid a year of COVID-19 pandemic
상태바
Global big pharma earnings amid a year of COVID-19 pandemic
  • Hyeokgi Lee, Newsmp
  • 승인 2021.08.09 15:50
  • 댓글 0
이 기사를 공유합니다

Major big pharma, sales surge in the second quarter… Pfizer, 92.4%↑

Global big pharmaceutical companies have overcome the stagnant growth amid the COVID-19 pandemic.

As Newsmp tallied the semi-annual reports of major global big pharmaceuticals, it was found that most of the big pharma recorded double-digit growth.

The company with the biggest growth was Pfizer, whose quarterly sales surged 92.4% from 11.27 trillion to 21.07 trillion won due to the COVID-19 vaccine (based on the exchange rate as of August 5).

Following Pfizer, AbbVie grew 33.9% and AstraZeneca 31.0%, while Johnson & Johnson, Eli Lilly, MSD, and Gilead Sciences exceeded more than 20% growth.

In particular, the vaccine manufacturer Pfizer, AstraZeneca, and Johnson & Johnson (Janssen) recorded considerable growth, over 20%.

GSK’s growth was close to 20%, and quarterly sales of BMS, Novartis, Roche, and Novo Nordisk also increased by more than 10%.

Sanofi and Amgen, which fell 4% in the first quarter, showed only single-digit growth but freed from the negative growth trend.

With the recovery in 2Q earnings, all of the semi-annual sales turned to growth. Pfizer’s 1H sales surged 68.2% YoY.

AbbVie’s sales also soared more than 40% due to the merger with Allergan, and AstraZeneca’s growth also exceeded 20%.

Meanwhile, Eli Lilly, Gilead Sciences, and MSD recorded double-digit growth.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.